FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331317937> ?p ?o ?g. }

• W2331317937 endingPage "227" @default.
• W2331317937 startingPage "217" @default.
• W2331317937 abstract "The fixed-dose, long-acting bronchodilator combination of umeclidinium/vilanterol (UMEC/VI) has not previously been compared with a combination of a long-acting muscarinic antagonist and long-acting β2-agonist in patients with chronic obstructive pulmonary disease (COPD). This 12-week, randomized, blinded, triple-dummy, parallel-group, non-inferiority study compared once-daily UMEC/VI 62.5/25 mcg with once-daily tiotropium (TIO) 18 mcg + indacaterol (IND) 150 mcg in patients with moderate-to-very-severe COPD. The primary endpoint was the trough forced expiratory volume in 1 s (FEV1) on day 85 (predefined non-inferiority margin −50 mL), and the secondary endpoint was the 0- to 6-h weighted mean (WM) FEV1 on day 84. Other efficacy endpoints [including rescue medication use, the Transition Dyspnea Index (TDI) focal score, and the St. George’s Respiratory Questionnaire (SGRQ) score] and safety endpoints [adverse events (AEs), vital signs, and COPD exacerbations] were also assessed. Trough FEV1 improvements were comparable between treatment groups [least squares (LS) mean changes from baseline to day 85: UMEC/VI 172 mL; TIO + IND 171 mL; treatment difference 1 mL; 95 % confidence interval (CI) −29 to 30 mL], demonstrating non-inferiority between UMEC/VI and TIO + IND. The treatments produced similar improvements in the trough FEV1 at other study visits and the 0- to 6-h WM FEV1 (LS mean changes at day 84: UMEC/VI 235 mL; TIO + IND 258 mL; treatment difference −23 mL; 95 % CI −54 to 8 mL). The results for patient-reported measures (rescue medication use, TDI focal score, and SGRQ score) were comparable; both treatments produced clinically meaningful improvements in TDI and SGRQ scores. The incidence of AEs and COPD exacerbations, and changes in vital signs were similar for the two treatments. UMEC/VI and TIO + IND, given once daily, provided similar improvements in lung function and patient-reported outcomes over 12 weeks in patients with COPD, with comparable tolerability and safety profiles. ClinicalTrials.gov study ID NCT02257385; GSK study no. 116961." @default.
• W2331317937 created "2016-06-24" @default.
• W2331317937 creator A5001826422 @default.
• W2331317937 creator A5036000357 @default.
• W2331317937 creator A5044702185 @default.
• W2331317937 creator A5076131242 @default.
• W2331317937 creator A5086177137 @default.
• W2331317937 date "2016-03-30" @default.
• W2331317937 modified "2023-10-11" @default.
• W2331317937 title "Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial" @default.
• W2331317937 cites W1978950822 @default.
• W2331317937 cites W2004780292 @default.
• W2331317937 cites W2017287154 @default.
• W2331317937 cites W2026585673 @default.
• W2331317937 cites W2039237831 @default.
• W2331317937 cites W2044624199 @default.
• W2331317937 cites W2044763202 @default.
• W2331317937 cites W2093577653 @default.
• W2331317937 cites W2105234929 @default.
• W2331317937 cites W2112433656 @default.
• W2331317937 cites W2125779455 @default.
• W2331317937 cites W2127951128 @default.
• W2331317937 cites W2141034778 @default.
• W2331317937 cites W2152766455 @default.
• W2331317937 cites W2166432084 @default.
• W2331317937 cites W3189355562 @default.
• W2331317937 cites W4211263216 @default.
• W2331317937 doi "https://doi.org/10.1007/s40268-016-0131-2" @default.
• W2331317937 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4875926" @default.
• W2331317937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27028749" @default.
• W2331317937 hasPublicationYear "2016" @default.
• W2331317937 type Work @default.
• W2331317937 sameAs 2331317937 @default.
• W2331317937 citedByCount "22" @default.
• W2331317937 countsByYear W23313179372016 @default.
• W2331317937 countsByYear W23313179372017 @default.
• W2331317937 countsByYear W23313179372018 @default.
• W2331317937 countsByYear W23313179372019 @default.
• W2331317937 countsByYear W23313179372020 @default.
• W2331317937 countsByYear W23313179372022 @default.
• W2331317937 crossrefType "journal-article" @default.
• W2331317937 hasAuthorship W2331317937A5001826422 @default.
• W2331317937 hasAuthorship W2331317937A5036000357 @default.
• W2331317937 hasAuthorship W2331317937A5044702185 @default.
• W2331317937 hasAuthorship W2331317937A5076131242 @default.
• W2331317937 hasAuthorship W2331317937A5086177137 @default.
• W2331317937 hasBestOaLocation W23313179371 @default.
• W2331317937 hasConcept C126322002 @default.
• W2331317937 hasConcept C142724271 @default.
• W2331317937 hasConcept C168563851 @default.
• W2331317937 hasConcept C197934379 @default.
• W2331317937 hasConcept C203092338 @default.
• W2331317937 hasConcept C204787440 @default.
• W2331317937 hasConcept C27081682 @default.
• W2331317937 hasConcept C2776042228 @default.
• W2331317937 hasConcept C2776780178 @default.
• W2331317937 hasConcept C2776968687 @default.
• W2331317937 hasConcept C2777714996 @default.
• W2331317937 hasConcept C2778884479 @default.
• W2331317937 hasConcept C2780911369 @default.
• W2331317937 hasConcept C2781018748 @default.
• W2331317937 hasConcept C3018587741 @default.
• W2331317937 hasConcept C42219234 @default.
• W2331317937 hasConcept C71924100 @default.
• W2331317937 hasConceptScore W2331317937C126322002 @default.
• W2331317937 hasConceptScore W2331317937C142724271 @default.
• W2331317937 hasConceptScore W2331317937C168563851 @default.
• W2331317937 hasConceptScore W2331317937C197934379 @default.
• W2331317937 hasConceptScore W2331317937C203092338 @default.
• W2331317937 hasConceptScore W2331317937C204787440 @default.
• W2331317937 hasConceptScore W2331317937C27081682 @default.
• W2331317937 hasConceptScore W2331317937C2776042228 @default.
• W2331317937 hasConceptScore W2331317937C2776780178 @default.
• W2331317937 hasConceptScore W2331317937C2776968687 @default.
• W2331317937 hasConceptScore W2331317937C2777714996 @default.
• W2331317937 hasConceptScore W2331317937C2778884479 @default.
• W2331317937 hasConceptScore W2331317937C2780911369 @default.
• W2331317937 hasConceptScore W2331317937C2781018748 @default.
• W2331317937 hasConceptScore W2331317937C3018587741 @default.
• W2331317937 hasConceptScore W2331317937C42219234 @default.
• W2331317937 hasConceptScore W2331317937C71924100 @default.
• W2331317937 hasFunder F4320307773 @default.
• W2331317937 hasIssue "2" @default.
• W2331317937 hasLocation W23313179371 @default.
• W2331317937 hasLocation W23313179372 @default.
• W2331317937 hasLocation W23313179373 @default.
• W2331317937 hasLocation W23313179374 @default.
• W2331317937 hasOpenAccess W2331317937 @default.
• W2331317937 hasPrimaryLocation W23313179371 @default.
• W2331317937 hasRelatedWork W1986963293 @default.
• W2331317937 hasRelatedWork W2171974515 @default.
• W2331317937 hasRelatedWork W2331317937 @default.
• W2331317937 hasRelatedWork W2482333537 @default.
• W2331317937 hasRelatedWork W2565055415 @default.
• W2331317937 hasRelatedWork W2589863829 @default.
• W2331317937 hasRelatedWork W333419345 @default.
• W2331317937 hasRelatedWork W4232328075 @default.
• W2331317937 hasRelatedWork W4234641545 @default.

• next